In Brief This Week: Response Biomedical; Sequenom; Allen Institute for Brain Science; Dotmatics; Riken | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical this week said that it has consolidated its stock on a 10 for one basis. The Vancouver, BC-based molecular diagnostics company said that the consolidation applies to all of its common shares, stock options, and warrants. Following the consolidation, Response Biomedical has 25,467,200 common shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.